ClinicalTrials.gg
CompletedNCT05553054GAME-OVERUpdated Jul 7, 2026

Drug Wastage : Observational Study in Intensive Care Units in France

An observational study in Drug Use, sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer. Completed at 61 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,066
Ages
18 Years and older
Sex
All
01

Study summary

Environmental awareness leads medical field to question its responsibility and possibilities for action.

Drug residues can have a major environmental impact as per their bioaccumulation, toxicity and persistence characteristics, depending on where they are discarded. In France, drug residues should be disposed of by incineration, but in practice, this is not systematic. Moreover, data on drug wastage in Intensive Care Units (ICU) are rare.

GAME-OVER observational study aims to evaluate drug wastage in ICU in France and to suggest ways to improve health care practices.

Read the detailed description

Observational study with data collection during a 24-hour business day. Data collected refer to healthcare team's practices and patients.

Collection starts when day shift starts (at 7:00 am) and ends when night shift leaves (at 7:00 am the following day).

02

Conditions studied

  • Drug Use

Keywords

  • Intravenous (IV) drug
  • Waste
  • Intensive Care Unit (ICU)
  • Environmental sustainability
  • Drug wastage
  • Care Eco-design
03

In context

Lead sponsor

Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer is the lead sponsor of 78 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients hospitalized in intensive care units during the 24 hours of data collection.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients hospitalized in intensive care units during the 24 hours of data collection.

Exclusion criteria

Exclusion Criteria:

  • Patient's opposition to participate in the study or patient family opposition if the patient is not able to be informed.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,066 participants (actual)
Patient registry
No

Groups and cohorts

  • Intravenous (IV) drugs

    Patient and prepared/administrated/discarded IV drugs data will be collected during 24 hours.

    Other: Quantification of IV drugs wastage

Interventions

  • OtherQuantification of IV drugs wastage

    Drugs are prescribed depending on physician discretion. Specific collection bins are provided to ICU. Healthcare teams discard syringes labelled with name and dilution which have been used to prepare drugs into these bins. After 24 hours of collection, bins are analyzed by investigators.

06

What researchers measure

Primary outcomes

  1. Ratio of overall wastage in milliliter (mL) of prepared and discarded IV drugs to overall volume in milliliter (mL) of prepared IV drugs.

    Wastage is defined as any prepared and unused drug that remains in syringe or IV bag.

    Time frame: 24 hours

Secondary outcomes

  1. Reason for discarding drug residues

    A questionnaire will be fulfilled by healthcare teams with the following possible categories: 1/ prepared in advance and not used ; 2/ systematic change at fixed times ; 3/ prescription change ; 4/ change by anticipation of care ; 5/ drug no longer needed ; 6/ preparation error ; 7/ other reason.

    Time frame: 24 hours

  2. Drug residues discarding process

    A questionnaire will be used to determine which discarding process are applied by nurses in their usual pratices.

    Time frame: 24 hours

  3. Use of enteral administration route

    Use of enteral administration route versus per os and IV routes will be analyzed for paracetamol and proton pump inhibitor according to the accessibility of enteral route and the reason and the date of patient entry in ICU.

    Time frame: 24 hours

  4. Cost of overall IV drug wastage

    Estimated cost of drug residues will be evaluated for each drug, according to the reason for discarding, by the following formula : volume of discarded IV drugs x theoretical price

    Time frame: 24 hours

07

Study locations

61 sites
  • Centre Hospitalier de Charleville-Mezieres
    Charleville-Mézières, Ardennes 08000, France
  • CHRU de Strasbourg
    Strasbourg, Bas-Rhin 67098, France
  • Hôpital Nord
    Marseille, Bouches Du Rhône 13015, France
  • Centre Hospitalier d'Aurillac
    Aurillac, Cantal 15000, France
  • Groupe Hospitalier Littoral Atlantique
    La Rochelle, Charente-Maritime 17019, France
  • CHU de Besançon
    Besançon, Doubs 25000, France
  • Centre Hospitalier de Montélimar
    Montélimar, Drôme 26216, France
  • Hôpital privé Claude Galien
    Quincy-sous-Sénart, Essonne 91480, France
  • HIA Clermont Tonnerre
    Brest, Finistère 29240, France
  • CHRU de Brest
    Brest, Finistère 29609, France
  • CHU de Nîmes
    Nîmes, Gard 30900, France
  • Clinique Saint Augustin
    Bordeaux, Gironde 33000, France
  • CHU de Bordeaux - Hôpital Pellegrin
    Bordeaux, Gironde 33076, France
  • HIA Robert Picqué
    Bordeaux, Gironde 33140, France
  • Hôpital Robert Boulin
    Libourne, Gironde 33500, France
  • CHU de Toulouse - Hôpital Purpan
    Toulouse, Haute Garonne 31059, France
  • Clinique la Croix du Sud
    Quint-Fonsegrives, Haute-Garonne 31130, France
  • CHU de Toulouse - Hôpital Rangueil
    Toulouse, Haute-Garonne 31059, France
  • Clinique Pasteur
    Toulouse, Haute-Garonne 31300, France
  • Centre Hospitalier Emile Roux
    Le Puy-en-Velay, Haute-Loire 43000, France
  • Hôpital privé d'Antony
    Antony, Hauts-de-Seine 92160, France
  • HIA Percy-Clamart
    Clamart, Hauts-de-Seine 92141, France
  • Hôpital Américain de Paris
    Neuilly-sur-Seine, Hauts-de-Seine 92200, France
  • CHU de Rennes
    Rennes, Ille-et-Vilaine 35033, France
  • CHRU de Tours
    Chambray-lès-Tours, Indre-et-Loire 37170, France
  • CHU de Grenoble
    La Tronche, Isère 38700, France
  • Centre Hospitalier de Dax
    Dax, Landes 40100, France
  • Centre Hospitalier de Mont-de-Marsan
    Mont-de-Marsan, Landes 40024, France
  • Centre Hospitalier Simone Veil
    Blois, Loir-et-Cher 41000, France
  • Centre Hospitalier de Saint Nazaire
    Saint-Nazaire, Loire-Atlantique 44600, France
  • Centre Hospitalier d'Orléans
    Orléans, Loiret 45100, France
  • Centre Hospitalier de Cahors
    Cahors, Lot 46005, France
  • CHU d'Angers
    Angers, Maine-et-Loire 49100, France
  • Centre Hospitalier Mémorial de Saint-Lô
    Saint-Lô, Manche 50000, France
  • CHU de Reims
    Reims, Marne 51100, France
  • Centre Hospitalier Bretagne Atlantique de Vannes
    Vannes, Morbihan 56017, France
  • CHU de Lille - Hôpital Huriez
    Lille, Nord 59037, France
  • CHU de Lille - Hôpital Roger Salengro
    Lille, Nord 59037, France
  • Centre Hospitalier du Forez
    Montbrison, Pays de la Loire Region 42600, France
  • CHU de Saint-Etienne
    Saint-Priest-en-Jarez, Pays de la Loire Region 42270, France
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, Puy-de-Dôme 63003, France
  • Hôpital Pierre Wertheimer
    Bron, Rhône 69677, France
  • Hôpital Edouard Herriot
    Lyon, Rhône 69003, France
  • Clinique de la Sauvegarde
    Lyon, Rhône 69009, France
  • CHU Félix-Guyon
    Saint-Denis, Réunion 97400, France
  • CHU de la Réunion
    Saint-Pierre, Réunion 97410, France
  • Grand Hôpital de l'Est Francilien
    Meaux, Seine-et-Marne 77100, France
  • CHU d'Amiens
    Amiens, Somme 80054, France
  • Hôpital Nord Franche-Comté
    Trévenans, Territoire De Belfort 90400, France
  • Centre Hospitalier Victor Dupouy
    Argenteuil, Val d'Oise 95100, France
  • Hôpital Henri Mondor
    Créteil, Val-de-Marne 94000, France
  • HIA Sainte Anne
    Toulon, Var 83000, France
  • Hôpital Sainte Musse
    Toulon, Var 83056, France
  • CHU de Poitiers
    Poitiers, Vienne 86021, France
  • Centre Hospitalier de Versailles
    Le Chesnay, Yvelines 78150, France
  • CHU Dupuytren
    Limoges, 87042, France
  • Hôpital Lariboisière
    Paris, 75010, France
  • Hôpital La Pitié-Salpétrière
    Paris, 75013, France
  • Hôpital Bichat
    Paris, 75018, France
  • Centre Hospitalier de Mayotte
    Mamoudzou, 97600, Mayotte
  • Centre Hospitalier Princesse Grace
    Monaco, 98000, Monaco
08

References and documents

Publications

  • Atchade E, Cungi PJ, Pons S, Dahyot-Fizelier C, Cesana M, Lukaszewicz AC, Bouhemad B, Trouiller P, Chelly J, Montravers P, Vardon F, D'Aranda E; SFAR Critical Care Committee; SFAR Sustainability Committee; SFAR Research Network; GAME-OVER Study group; GAME-OVER investigators group. Characteristics of French intensive care units and patients: an ancillary analysis of the GAME-OVER study. BMC Anesthesiol. 2025 Dec 5;26(1):27. doi: 10.1186/s12871-025-03473-5. PubMed 41345913 ↗
  • d'Aranda E, Cungi PJ, Chelly J, Pons S; GAME-OVER Study Group, GAME-OVER Study Investigators, French Society of Anesthesia & Intensive Care Medicine (SFAR) Sustainability; Committee, SFAR Critical Care Committee, and SFAR Research Network; GAME-OVER Study Group, GAME-OVER Study Investigators, French Society of Anesthesia & Intensive Care Medicine (SFAR) Sustainability and Committee, SFAR Critical Care Committee, and SFAR Research Network. Sustainable Intensive Care: Do Not Forget IV to Oral Switch! Crit Care Med. 2026 Jan 1;54(1):218-223. doi: 10.1097/CCM.0000000000006944. Epub 2026 Jan 6. No abstract available. PubMed 41493367 ↗
  • d'Aranda E; GAME-OVER investigators group; Pons S, Chelly J, Atchade E, Bonnet L; SFAR Sustainable Development Committee; Dahyot-Fizelier C; SFAR Critical Care Committee; Kamel T, Giannoni F, Collange O, Besnier E, Schoeffler M, Mayeur N, Quere PL, Marecal L, Pernod C, Geay C, Esnault P, Cinotti R; SFAR Research Network; Cesana M, Cungi PJ. Correction: Discarded intravenous medication in the ICU: the GAME-OVER multicenter prospective observational study. Crit Care. 2026 Jan 21;30(1):32. doi: 10.1186/s13054-025-05822-9. No abstract available. PubMed 41566365 ↗
  • d'Aranda E; GAME-OVER investigators group; Pons S, Chelly J, Atchade E, Bonnet L; SFAR Sustainable Development Committee; Dahyot-Fizelier C; SFAR Critical Care Committee; Kamel T, Giannoni F, Collange O, Besnier E, Schoeffler M, Mayeur N, Quere PL, Marecal L, Pernod C, Geay C, Esnault P, Cinotti R; SFAR Research Network; Cesana M, Cungi PJ. Discarded intravenous medication in the ICU: the GAME-OVER multicenter prospective observational study. Crit Care. 2025 Feb 21;29(1):84. doi: 10.1186/s13054-025-05299-6. PubMed 39985053 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05553054
Lead sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborators
Sainte-Anne Military Teaching Hospital
Responsible party
Sponsor
First posted
Sep 23, 2022
Start date
Nov 8, 2022
Primary completion
Mar 15, 2023
Completion
Mar 15, 2023
Last update
Jul 7, 2026

Study contacts

Erwan D'ARANDA, MD
study director · Sainte-Anne Military Teaching Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion